STOCK TITAN

RFL CFO reports tax withholding on RSU vesting; 260,641 shares held

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Rafael Holdings (RFL) disclosed a Form 4 for its Chief Financial Officer. On 10/25/2025, 4,180 shares of Class B common stock were withheld for taxes upon the vesting of restricted stock, coded F, at a price of $1.35 per share.

Following this transaction, the CFO beneficially owns 260,641 shares directly. This total consists of 76,882 shares held directly, 82,509 fully vested restricted shares, and 101,250 unvested restricted shares.

The unvested restricted shares vest as follows: 6,250 quarterly from December 21, 2025 through December 21, 2026; 10,000 on each of October 25, 2026 and October 25, 2027; and 12,500 on each of January 13, 2026, January 13, 2027, January 13, 2028, and January 13, 2029.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Polinsky David

(Last) (First) (Middle)
C/O RAFAEL HOLDINGS, INC.
520 BROAD ST

(Street)
NEWARK NJ 07102

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Rafael Holdings, Inc. [ RFL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class B Common Stock, par value $.01 per share 10/25/2025 F 4,180(1) D $1.35 260,641(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares withheld by the Issuer for tax purposes upon the vesting of Restricted Stock.
2. Consists of 76,882 shares held directly, 82,509 fully vested restricted shares and 101,250 unvested restricted shares that vest as follows: 6,250 quarterly from December 21, 2025 through December 21, 2026; 10,000 on each of October 25, 2026 and October 25, 2027; and 12,500 on each of January 13, 2026, January 13, 2027, January 13, 2028 and January 13, 2029.
Joyce J. Mason, by Power of Attorney 10/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Rafael Holdings (RFL) disclose in this Form 4?

The CFO had 4,180 Class B shares withheld for taxes at $1.35 upon RSU vesting on 10/25/2025 (code F).

How many shares does the RFL CFO beneficially own after the transaction?

Beneficial ownership is 260,641 shares, held directly.

What makes up the CFO’s 260,641-share total at RFL?

It includes 76,882 shares held directly, 82,509 fully vested restricted shares, and 101,250 unvested restricted shares.

What is the vesting schedule for the unvested restricted shares at RFL?

6,250 quarterly from Dec 21, 2025 to Dec 21, 2026; 10,000 on Oct 25, 2026 and Oct 25, 2027; 12,500 on Jan 13 in 2026–2029.

What does transaction code F mean in a Form 4?

Code F indicates shares withheld by the issuer to cover taxes upon the vesting of restricted stock.

Which class of stock was involved in the RFL Form 4?

The transaction involved Class B common stock, par value $0.01 per share.
Rafael Holdings

NYSE:RFL

RFL Rankings

RFL Latest News

RFL Latest SEC Filings

RFL Stock Data

62.12M
31.81M
55.75%
10.92%
0.13%
Real Estate Services
Pharmaceutical Preparations
Link
United States
NEWARK